When a substance long associated with easing nausea becomes the hidden cause of relentless vomiting, medicine is forced to confront the limits of its own assumptions. On October 1st, the World Health Organization granted cannabis hyperemesis syndrome its first official diagnostic code — R11.16 — bringing a poorly understood and frequently misidentified condition out of the shadows of medical record-keeping. The change is administrative in form but consequential in meaning: patients who have cycled through emergency rooms for years, accumulating debt and misdiagnoses, may now be seen and counte
ScienceDaily
· Nov 25, 2025
· health
· 3 min read
High
Sourcing: Verified
New ICD Code Clarifies Cannabis Hyperemesis Syndrome as ER Visits Rise
Patients experience recurring severe vomiting episodes requiring emergency department visits costing thousands of dollars, with some enduring multiple visits before correct diagnosis.
◉
Health & Medicine
8412 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Bias & Framing
⚖
Article presents cannabis hyperemesis syndrome diagnosis code as neutral medical advancement with balanced reporting on clinical benefits and knowledge gaps.
Bias Direction
center
Confidence
MED
Medical/scientific framing emphasizing clinical utility and data accuracy. Presents the ICD code addition as a procedural improvement without advocacy for or against cannabis use.
severe vomiting condition
growing problem
adverse health effects
adverse events
Cannabis industry or legalization advocates' perspective on the classification
Patient experiences or testimonials from those with the syndrome
Comparison of prevalence rates before/after legalization in different jurisdictions
Alternative or complementary treatment approaches beyond standard medical care
Epidemiological context: how common this syndrome is relative to other cannabis-related conditions
Geopolitical Impact
🌎
WHO's new diagnostic code for cannabis hyperemesis syndrome is a public health classification update with no direct geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
WHO's new diagnostic code for cannabis hyperemesis syndrome enables better medical tracking and billing, potentially increasing healthcare costs as ER visits rise and cases become formally documented.
Market Signal
mixed
Confidence
MED
Healthcare/Hospitals
Pharmaceutical/Medical devices
Health Insurance
Cannabis industry
Public health
Consumers may face higher healthcare costs due to increased ER visits and improved diagnosis leading to more documented cases. Better diagnosis could reduce unnecessary tests and repeated visits long-term, but short-term costs may rise as awareness increases.
Potential regulatory scrutiny of cannabis products; possible insurance coverage discussions; public health campaigns about cannabis risks; potential restrictions on cannabis marketing or potency; healthcare system resource allocation for treating cannabis-related conditions.